Antonia Salud Salvia

Carrato, A; Benavides, M; Massuti, B; Ferreiro-Monteagudo, R; García Alfonso P; Falco, E; Reboredo, M; Cano, T; Gallego, J; Vieitez, JM; Layos, L; Salud, A; Polo, E; Dotor, E; Duran-Ogalla, G; Rodriguez-Garrote, M; Calvo, A; Grande, E; Aranda, E

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Bmc Cancer 19 533-533. 03/06/2019.

[doi:10.1186/s12885-019-5753-7]

Rivera, F; Romero, C; Jimenez-Fonseca, P; Izquierdo-Manuel, M; Salud, A; Martinez, E; Jorge, M; Arrazubi, V; Mendez, JC; Garcia-Alfonso, P; Reboredo, M; Barriuso, J; Muñoz-Unceta N; Jimeno, R; Lopez, C

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

CANCER CHEMOTHERAPY AND PHARMACOLOGY 83 1175-1181. 01/06/2019.

[doi:10.1007/s00280-019-03820-7]

Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Salazar R; Aranda E

Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial

ANNALS OF ONCOLOGY 30 796-803. 01/05/2019.

[doi:10.1093/annonc/mdz082]

MORALES MURILLO, SERAFIN; GASOL CUDOS, ARIADNA; VELASCO SANCHEZ, ANA; MARTINEZ ORTIN, DAVID; SALLA FORTUNY, JOEL; TEJERO NARBONA, RUBEN; SERRATE LOPEZ, ANNA ALBA; VILARDELL VILLELLAS, FELIPE; SALUD SALVIA, ANTONIA

Clinical and Biological Factors Associated with ISH Amplification in HER2 2+ by IHC in Breast Cancer Patients

Biomedical Journal of Scientific & Technical Research -. 28/03/2019.

[doi:10.26717/BJSTR.2019.16.002860]

Diaz-Serrano, A; Angulo, B; Dominguez, C; Pazo-Cid, R; Salud, A; Jimenez-Fonseca, P; Leon, A; Galan, MC; Alsina, M; Rivera, F; Plaza, JC; Paz-Ares, L; Lopez-Rios, F; Gomez-Martin, C

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab

Oncologist 23 1092-1102. 01/09/2018.

[doi:10.1634/theoncologist.2017-0379]

Alonso, V; Escudero, P; Fernandez-Martos, C; Salud, A; Mendez, M; Gallego, J; Rodriguez, JR; Martin-Richard, M; Fernandez-Plana, J; Manzano, H; Mendez, JC; Zanui, M; Falco, E; Gil-Raga, M; Rojo, F; Cuatrecasas, M; Feliu, J; Garcia-Albeniz, X; Maurel, J

Coexpression of p-IGF-1R and MMP-7 Modulates Panitumumab and Cetuximab Efficacy in RAS Wild-Type Metastatic Colorectal Cancer Patients

NEOPLASIA 20 678-686. 01/07/2018.

[doi:10.1016/j.neo.2018.05.004]

Feliu, J; Salud, A; Losada, EP; Alonso, V; Cubillo, A; Soler, G

First-line treatment with panitumumab plus FOLFIRI in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good performance status: OPALO trial.

Journal of Clinical Oncology 36 -. 20/05/2018.

[doi:10.1200/JCO.2018.36.15_suppl.TPS3618]

Codony-Servat, J; Cuatrecasas, M; Asensio, E; Montironi, C; Martinez-Cardus, A; Marin-Aguilera, M; Horndler, C; Martinez-Balibrea, E; Rubini, M; Jares, P; Reig, O; Victoria, I; Gaba, L; Martin-Richard, M; Alonso, V; Escudero, P; Fernandez-Martos, C; Feliu, J; Mendez, JC; Mendez, M; Gallego, J; Salud, A; Rojo, F; Castells, A; Prat, A; Rosell, R; Garcia-Albeniz, X; Camps, J; Maurel, J

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

BRITISH JOURNAL OF CANCER 117 1777-1786. 05/12/2017.

[doi:10.1038/bjc.2017.279]

Porcel, JM; Sole, C; Salud, A; Bielsa, S

Prognosis of Cancer with Synchronous or Metachronous Malignant Pleural Effusion

Lung 195 775-779. 01/12/2017.

[doi:10.1007/s00408-017-0050-1]

Vallez-Valero, L.; Rius-Perera, J.; Gilabert Sotoca, M.; Mangues-Bafalluy, I; Schoenenberger, J. A.; Salud-Salvia, M. A.

USE OF ABIRATERONE AND ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT-PROSTATE CANCER IN ROUTINE CLINICAL PRACTICE

VALUE IN HEALTH 20 417-417. 01/10/2017.

[doi:10.1016/j.jval.2017.08.114]

Novell, A; Morales, S; Valls J; Panades, MJ; Salud, A; Iglesias, E; Vilardell, F; Matias-Guiu, X; Llombart-Cussac, A

Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases

HISTOLOGY AND HISTOPATHOLOGY 32 909-915. 01/09/2017.

[doi:10.14670/HH-11-849]

Sastre, J.; de la Orden, V.; Martinez, A.; Bando, I.; Santamaria, I.; Bellosillo Paricio, B.; Palanca, S.; Peligros, I.; Mediero, B.; Llovet, P.; Moreno, V.; Vieitez, J. M.; Garcia-Alfonso, P.; Gil, S.; Ortiz Morales, M. J.; Salud Salvia, M. A.; Quintero, G.; Gesto, F. A.; Aranda Aguilar, E.; Diaz Rubio, E.

Circulating tumor cells (CTCs), molecular alterations and their correlation with characteristics of patients (pts) with metastatic colorectal cancer (mCRC) treated in the Spanish TTD VISN & Uacute; Program

ANNALS OF ONCOLOGY 28 -. 01/09/2017.